Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1588
Peer-review started: October 5, 2023
First decision: December 6, 2023
Revised: December 20, 2023
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: March 21, 2024
Processing time: 168 Days and 9.2 Hours
Acute liver failure (ALF) has a high mortality with widespread hepatocyte death involving ferroptosis and pyroptosis, but their precise role in ALF is unknown. Silent information regulator sirtuin 1 (SIRT1)-mediated deacetylation influences multiple biological processes, including cellular senescence, apoptosis, sugar and lipid metabolism, oxidative stress, and inflammation. In this study, we examined the link between ferroptosis and pyroptosis and the upstream regulatory mechanisms.
The most effective treatment for ALF at present is liver transplantation. However, liver transplants are not widely available because of the lack of donors and the high cost of medical care. Therefore, therapies for ALF are imminent.
To explore the link between ferroptosis and pyroptosis and the upstream regulatory mechanisms.
Animal and cellular models of ALF were developed. The levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were tested with automatic biochemistry instrument. Iron, reactive oxygen species, and glutathione levels were measured using commercial kits. SIRT1, p53, acetylated p53 (Ac-p53), glutathione peroxidase 4 (GPX4), gasdermin D (GSDMD), solute carrier family 7a member 11 (SLC7A11), and acyl-CoA synthetase long-chain family member 4 (ACSL4) protein expression levels were measured through Western blot analysis.
AST and ALT levels were elevated in the serum of ALF patients. SIRT1, SLC7A11, and GPX4 expressions were decreased and Ac-p53, p53, GSDMD, and ACSL4 levels were elevated in human ALF liver tissue. In p53 and ferroptosis inhibitor–treated and GSDMD-/- groups, serum interleukin (IL)-1β, tumour necrosis factor alpha, IL-6, IL-2, and C-C motif ligand 2 levels were decreased and hepatic impairment was mitigated. In mice with GSDMD knockout, p53 was reduced, GPX4 was increased, and ferroptotic events (depletion of SLC7A11, elevation of ACSL4, and iron accumulation) were detected.
SIRT1 activation attenuates lipopolysaccharide/D-galactosamine-induced ferroptosis and pyroptosis by inhibiting the p53/GPX4/GSDMD signaling pathway in ALF.
Our research is only limited to cellular and mouse models and has not been applied to clinical studies. Although we found decreased SIRT1 expression in human ALF liver tissue, whether SIRT1 activator is effective for acute liver injury and failure in patients is unknown, and further safety and efficacy studies are required.
